You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 3
  • 36 Prognostic value and association with veliparib benefit of modeled CA-125 elimination kinetics (KELIM) in patients with newly diagnosed ovarian cancer: analysis from the VELIA/GOG-3005 study

Citation Tools

Article menu

Download PDFPDF

Oral Poster – TAPED
Oral Featured Posters – Pre-Recorded
IGCS20_1102
36 Prognostic value and association with veliparib benefit of modeled CA-125 elimination kinetics (KELIM) in patients with newly diagnosed ovarian cancer: analysis from the VELIA/GOG-3005 study
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
You B, Fleming G, Bookman M, et al
36 Prognostic value and association with veliparib benefit of modeled CA-125 elimination kinetics (KELIM) in patients with newly diagnosed ovarian cancer: analysis from the VELIA/GOG-3005 study
International Journal of Gynecologic Cancer 2020;30:A24-A25.